Abstract: The invention provides a novel solid pharmaceutical dosage form which includes an opiate, an opiate antagonist admixed with the analgetic (opiate agonist) and an amount of a hydrocolloid containing excipient which is effective to form a non-injectable slurry when the dosage form is contacted with water. In addition the dosage form contains pure naloxone in enteric coated form which is designed to release in the colon to prevent or relieve constipation. Thus the formulation, because of the enteric coated naloxone and the hydrocolloid excipient(s), has reduced side effects as compared with formulations which do not contain these features.

Abstract: An airbag inflator (10) including an elongated outer housing (12) having an interior and a plurality of orifices (22) extending collinearly therealong to enable fluid communication between the outer housing interior and an exterior of the outer housing (12). The outer housing orifice(s) (22) open from the outer housing interior toward a first side (F) of the inflator. An elongated inner housing (14) is positioned in the outer housing interior. The inner housing (14) has an interior and a plurality of orifices (20) extending collinearly therealong to enable fluid communication between the inner housing interior and an exterior of the inner housing (14). The inner housing orifice(s) (20) open from the inner housing interior toward a second side (S) of the inflator. A quantity of a gas generant composition (16) extends along a portion of the interior of the inner housing (14).

Abstract: HIV infections are treated with sequential treatment regimens comprising a first regimen which is a combination of highly active antiretroviral therapy drugs selected from the group consisting of nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors to reduce the HIV levels; and a second treatment regimen which is administered after said HIV levels are reduced or resistance is observed, said second treatment regimen an amount of an HIV entry/fusion inhibitor to form a modified treatment regimen and continuing to administer said modified treatment regimen for a period of from 10 to 30 days.

Abstract: The invention provides a novel solid pharmaceutical dosage form which includes an opiate, an opiate antagonist admixed with the analgetic (opiate agonist) and an amount of a hydrocolloid containing excipient which is effective to form a non-injectable slurry when the dosage form is contacted with water. In addition the dosage form contains pure naloxone in enteric coated form which is designed to release in the colon to prevent or relieve constipation. Thus the formulation, because of the enteric coated naloxone and the hydrocolloid excipient(s), has reduced side effects as compared with formulations which do not contain these features.

Abstract: This invention concerns a method for decreasing both the oral and parenteral abuse potential of strong analgetic agents such as oxycodone, propoxyphene and pentazocine by combining an analgesic dose of the analgetic agents with naloxone in specific, relatively narrow ranges. Oxycodone-naloxone compositions having a ratio of 2.5-5:1 parts by weight and pentazocine-naloxone compositions having a ratio of 16-50:1 parts by weight are preferred.

Abstract: Method of promoting growth and improving feed efficiency in economically important animals which comprises the oral administration to said animals of feed containing an effective amount of amphomycin.

Abstract: Bacteroides which are uniformly resistant to ceftazidime fail to grow when exposed to 2.beta.-chloromethyl-2.alpha.-methylpenam-3.alpha.-carboxylic acid (BL-P 2013), which itself is non-inhibitory, in combination with ceftazidime. Bacteroides infections are abated by treatment of the infected mammal with this combination of substances.

Abstract: Enhanced antiulcer activity is obtained in warm-blooded animals by the concomitant administration of the histamine H.sub.2 -receptor antagonist, etintidine, and the pepsin complexing agent, pepstatin. Concomitant administration of the two entities reduces the amount of etintidine necessary for effective treatment, thereby decreasing its side effect liability.

Abstract: N-Allyl-benzmorphan compounds having structures distinguished by having either a 4,5 or 6 carbon containing allyl group at the 2- or N-position or various ether derivatives of the 2'-hydroxy group. The compounds are prepared by alkylation of appropriate N-nor bases and have analgetic antagonist activity particularly pronounced in countering the effects of overdosing. Certain N-acyl-2'-hydroxy-5,9-dimethyl-6,7-benzmorphan intermediates are also disclosed.

Abstract: dl-N-Cyclopropylmethyl-3-hydroxy-9-azamorphinan is a compound known to possess analgesic activity that is about twice as potent as pentazocine. Resolution of the compound into its levorotatory and dextrorotatory isomers and subsequent animal testing revealed that l-N-cyclopropylmethyl-3-hydroxy-9-azamorphinan was much more potent than the dl-mixture.

Abstract: Orally effective, analgetic compositions have been developed which are useful in the prevention of drug abuse because upon parenteral administration, they do not produce analgesia, euphoria, or physical dependence. Such compositions comprise an orally active, strong analgetic in oral dosage form and containing, for each analgetic dose of the analgetic agent, an amount of naloxone sufficient, upon parenteral administration of said oral dosage form, to negate the analgetic, euphoretic and dependence producing action of the composition, but insufficient to block the therapeutic effect of the analgetic when the admixture is taken orally.